SCHEDULE 13D/A: Major Shareholder Amends Royalty Pharma Stake, Discloses Recent Share Sales

Sentiment:

Schedule 13D Amendment 21 February 2025 9:30 PM

R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini have filed an amended Schedule 13D for Royalty Pharma plc, revealing a beneficial ownership of 8.3% and significant share sales in the past 60 days.

Worse than expectedThe reporting persons, through their sub-funds, sold over 3.19 million Class A Ordinary Shares in the open market within a 60-day period.While they still retain a significant 8.3% stake, such large-scale selling by a major holder can be perceived negatively by the market, suggesting a reduction in conviction or a need for liquidity.

Summary

This document is Amendment No. 5 to the Schedule 13D filing concerning Royalty Pharma plc's Class A Ordinary Shares.
The reporting persons are R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini.
As of February 20, 2025, the reporting persons collectively beneficially own 36,001,535 Class A Ordinary Shares.
This ownership represents 8.3% of the outstanding Class A Shares, based on 433,324,905 shares outstanding as of February 7, 2025, as reported in the Issuer's Annual Report on Form 10-K.
The shares are held by MGG Strategic (19,774,062 shares) and GG Strategic (16,227,473 shares), which are sub-funds managed by MGG SICAF and GG 1978 SICAF, respectively.
R & H Trust Co. (Guernsey) Limited serves as the trustee, and Achille G. Severgnini as the protector, of the underlying trusts (MGG Trust and GG Trust) that economically own these shares.
Both reporting persons and other associated individuals explicitly disclaim beneficial ownership over the shares.
Significant sales of Class A Ordinary Shares occurred in the 60 days prior to February 20, 2025, with a combined total of 3,196,549 shares sold in the open market by GG Strategic and MGG Strategic.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant volume of shares sold by a major beneficial owner, which could be interpreted as a reduction in confidence or a strategic divestment, despite the remaining substantial stake.

Negatives

The reporting persons, through GG Strategic and MGG Strategic, sold a combined total of 3,196,549 Class A Ordinary Shares in the open market during the 60-day period ending February 20, 2025.
These sales occurred at average prices ranging from approximately $30.07 to $33.22 per share, potentially indicating a reduction in conviction or a strategic divestment by a major holder.

Future Outlook

Industry Context

This filing reflects a change in a significant institutional investor's stake in Royalty Pharma plc, a company focused on acquiring pharmaceutical royalties. Such changes can influence market perception of the stock, especially if large blocks of shares are sold, potentially signaling a shift in the investor's strategy or outlook on the pharmaceutical royalty market.

Stakeholder Impact

Shareholders: The sale of a significant number of shares by a major holder could lead to negative market sentiment and potential downward pressure on the stock price.

Key Dates

Date	Description
2020-06-29	Original Schedule 13D filed with the SEC.
2022-04-05	Amendment No. 1 to Schedule 13D filed with the SEC.
2022-08-11	Amendment No. 2 to Schedule 13D filed with the SEC.
2022-10-04	Amendment No. 3 to Schedule 13D filed with the SEC.
2024-07-29	Amendment No. 4 to Schedule 13D filed with the SEC.
2025-01-17	First reported sale of Class A Ordinary Shares by GG 1978 SICAF SIF S.A. GG Strategic.
2025-02-07	Date as of which 433,324,905 Class A Shares were outstanding, as reported in the Issuer's Annual Report on Form 10-K.
2025-02-12	Issuer's Annual Report on Form 10-K filed with the SEC.
2025-02-18	First reported sale of Class A Ordinary Shares by MGG Strategic SIC AF SIF S.A. MGG Strategic.
2025-02-19	Date of event which requires filing of this statement (Amendment No. 5).
2025-02-20	End date of the 60-day period for reported share sales.
2025-02-21	Date of signing of the Schedule 13D/A by R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini.

Recommendation

hold

Keywords

Royalty Pharma plc, Schedule 13D/A, Beneficial Ownership, Class A Ordinary Shares, Share Sales, Institutional Investor, SEC Filing, R & H Trust Co. (Guernsey) Limited, Achille G. Severgnini, MGG Strategic, GG Strategic, Equity Stake

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.